Press coverage about SCYNEXIS (NASDAQ:SCYX) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies negative and positive news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. SCYNEXIS earned a news impact score of 0.10 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 45.5931191051871 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

SCYNEXIS (NASDAQ:SCYX) traded up $0.03 during trading on Friday, reaching $1.88. The company’s stock had a trading volume of 45,989 shares, compared to its average volume of 159,851. The company has a current ratio of 7.30, a quick ratio of 7.30 and a debt-to-equity ratio of 0.43. SCYNEXIS has a 12 month low of $1.52 and a 12 month high of $4.04.

SCYX has been the topic of several research reports. HC Wainwright set a $14.00 target price on SCYNEXIS and gave the company a “buy” rating in a report on Wednesday, August 16th. Roth Capital set a $9.00 target price on SCYNEXIS and gave the company a “buy” rating in a report on Monday, August 7th. Zacks Investment Research raised SCYNEXIS from a “hold” rating to a “buy” rating and set a $2.00 target price on the stock in a report on Wednesday, August 2nd. Finally, Guggenheim initiated coverage on SCYNEXIS in a report on Tuesday, October 24th. They issued a “buy” rating and a $6.00 target price on the stock. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $8.43.

COPYRIGHT VIOLATION NOTICE: “Somewhat Favorable Media Coverage Somewhat Unlikely to Impact SCYNEXIS (SCYX) Share Price” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The legal version of this story can be read at


SCYNEXIS, Inc is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo in animal studies against a range of Candida and Aspergillus species, including drug-resistant strains.

Insider Buying and Selling by Quarter for SCYNEXIS (NASDAQ:SCYX)

Receive News & Ratings for SCYNEXIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SCYNEXIS Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.